Advertisement

Recombinant human soluble thrombomodulin and short-term mortality of infection patients with DIC: a meta-analysis

  • Author Footnotes
    1 The authors contribute equally to the work.
    Chao Zhang
    Footnotes
    1 The authors contribute equally to the work.
    Affiliations
    Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
    Search for articles by this author
  • Author Footnotes
    1 The authors contribute equally to the work.
    Huijuan Wang
    Footnotes
    1 The authors contribute equally to the work.
    Affiliations
    Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
    Search for articles by this author
  • Huqin Yang
    Affiliations
    Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
    Search for articles by this author
  • Zhaohui Tong
    Correspondence
    Corresponding author at: Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine, Beijing Chao-Yang Hospital, Capital Medical University, No. 8, Gong Ti South Rd, Chao-Yang District, Beijing 100020, China.
    Affiliations
    Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
    Search for articles by this author
  • Author Footnotes
    1 The authors contribute equally to the work.

      Abstract

      Objective

      Several studies have demonstrated that recombinant human soluble thrombomodulin (rhTM) has potential advantages for the treatment for patients with infection complicated by disseminated intravascular coagulation (DIC). However, whether injection of rhTM can affect the mortality of those patients in clinical treatment remains controversial. Therefore, we conducted a meta-analysis to evaluate the clinical efficacy for patients with infection complicated by DIC.

      Methods

      The PubMed, Web of Science, Embase, and Cochrane Library databases were searched for relevant articles that met the inclusion criteria through April 2016. Reference lists of the retrieved articles were also reviewed. The 28- or 30-day mortality and bleeding risk after using rhTM were evaluated.

      Results

      Ten observational studies and 2 randomized controlled trials (RCTs) involving 18 288 patients were included in this meta-analysis. The risk ratio for the 28- or 30-day mortality was 0.81 (95% confidence interval, 0.61-1.06) in RCT studies and 0.96 (95% confidence interval, 0.92-1.01) in observational studies. There were no significant differences in the bleeding risk between the rhTM group and the control group.

      Conclusion

      Based on the current studies, using rhTM for the treatment for infection patients complicated with DIC does not decrease the short-term mortality of those patients. More high-quality RCT studies need to be performed to confirm this finding.
      To read this article in full you will need to make a payment
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Emergency Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ito T
        • Maruyama I
        Thrombomodulin: protectorate god of the vasculature in thrombosis and inflammation.
        J Thromb Haemost. 2011; 9: 168-173
        • Toh CH
        • Dennis M
        Disseminated intravascular coagulation: old disease, new hope.
        BMJ. 2003; 327: 974-977
        • Wada H
        • Wakita Y
        • Nakase T
        • Shimura M
        • Hiyoyama K
        • Nagaya S
        • et al.
        Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun, Mie DIC Study Group.
        Thromb Haemost. 1995; 74: 848-852
        • Gando S
        • Saitoh D
        • Ishikura H
        • Ueyama M
        • Otomo Y
        • Oda S
        • et al.
        A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis.
        Crit Care. 2013; 17: R297
        • Zarychanski R
        • Abou-Setta AM
        • Kanji S
        • Turgeon AF
        • Kumar A
        • Houston DS
        • et al.
        The efficacy and safety of heparin in patients with sepsis: a systematic review and meta analysis.
        Crit Care Med. 2015; 43: 511-518
        • Dellinger RP
        • Levy MM
        • Carlet JM
        • Bion J
        • Parker MM
        • Jaeschke R
        • et al.
        Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008.
        Crit Care Med. 2008; 36: 296-327
        • Di Nisio M
        • Baudo F
        • Cosmi B
        • D'Angelo A
        • De Gasperi A
        • Malato A
        • et al.
        Diagnosis and treatment of disseminated intravascular coagulation: guidelines of the Italian Society for Haemostasis and Thrombosis (SISET).
        Thromb Res. 2012; 129: e177-e184
        • Iba T
        • Gando S
        • Thachil J
        Anticoagulant therapy for sepsis-associated disseminated intravascular coagulation: the view from Japan.
        J Thromb Haemost. 2014; 12: 1010-1019
        • Wada H
        • Matsumoto T
        • Yamashita Y
        Diagnosis and treatment of disseminated intravascular coagulation (DIC) according to four DIC guidelines.
        J Intensive Care Med. 2014; 2: 15
        • Miyoshi S
        • Ito R
        • Katayama H
        • Dote K
        • Aibiki M
        • Hamada H
        • et al.
        Combination therapy with sivelestat and recombinant human soluble thrombomodulin for ARDS and DIC patients.
        Drug Des Devel Ther. 2014; 8: 1211-1219
        • Hayakawa K
        • Tamura S
        • Gima H
        • Hayakawa T
        • Kurihara T
        • Ooura M
        • et al.
        Successful treatment of chronic disseminated intravascular coagulation using recombinant human soluble thrombomodulin in a dialysis patient with dissecting aortic aneurysm.
        Rinsho Ketsueki. 2014; 55: 2300-2305
        • Murata A
        • Okamoto K
        • Mayumi T
        • Muramatsu K
        • Matsuda S
        Recent change in treatment of disseminated intravascular coagulation in Japan:an epidemiological study based on a national administrative database.
        Clin Appl Thromb Hemost. 2016; 22: 21-27
        • Iba T
        • Thachil J
        Present and future of anticoagulant therapy using antithrombin and thrombomodulin for sepsis–associated disseminated intravascular coagulation: a perspective from Japan.
        Int J Hematol. 2016; 103: 253-261
        • Yamakawa K
        • Aihara M
        • Ogura H
        • Yuhara H
        • Hamasaki T
        • Shimazu T
        Recombinant human soluble thrombomodulin in severe sepsis: a systematic review and meta-analysis.
        J Thromb Haemost. 2015; 13: 508-519
        • Moher D
        • Liberati A
        • Tetzlaff J
        • Altman DG
        • PRISMA Group
        Reprint—preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
        Phys Ther. 2009; 89: 873-880
        • Higgins JPT
        • Green S
        Cochrane Handbook for Systematic Review of Interventions Version 5.1.0. [updated in March 2011].
        The Cochrane collaboration. 2011 ([Available from: http://www.cochrane-handbook.org])
        • Vincent JL
        • Ramesh MK
        • Ernest D
        • LaRosa SP
        • Pachl J
        • Aikawa N
        • et al.
        A randomized, double-blind, placebo-controlled, phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART–123, in patients with sepsis and suspected disseminated intravascular coagulation.
        Crit Care Med. 2013; 41: 2069-2079
        • Murata A
        • Okamoto K
        • Mayumi T
        • Muramatsu K
        • Matsuda S
        Observational study to compare antithrombin and thrombomodulin for disseminated intravascular coagulation.
        Int J Clin Pharm. 2015; 37: 139-147
        • Hayakawa M
        • Yamakawa K
        • Saito S
        • Uchino S
        • Kudo D
        • Iizuka Y
        • et al.
        Recombinant human soluble thrombomodulin and mortality in sepsis-induced disseminated intravascular coagulation: a multicentre retrospective study.
        Thromb Haemost. 2016; 115: 1157-1166
        • Yamato M
        • Minematsu Y
        • Fujii J
        • Mori K
        • Minato T
        • Miyagawa S
        • et al.
        Effective combination therapy of polymyxin-B direct hemoperfusion and recombinant thrombomodulin for septic shock accompanied by disseminated intravascular coagulation: a historical controlled trial.
        Ther Apher Dial. 2013; 17: 472-476
        • Saito H
        • Maruyama I
        • Shimazaki S
        • Yamamoto Y
        • Aikawa N
        • Ohno R
        • et al.
        Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial.
        J Thromb Haemost. 2007; 5: 31-41
        • Aikawa N
        • Shimazaki S
        • Yamamoto Y
        • Saito H
        • Maruyama I
        • Ohno R
        • et al.
        Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial.
        Shock. 2011; 35: 349-354
        • Tagami T
        • Matsui H
        • Fushimi K
        • Yasunaga H
        Use of recombinant human soluble thrombomodulin in patients with sepsis-induced disseminated intravascular coagulation after intestinal perforation.
        Front Med (Lausanne). 2015; 2: 7
        • Tagami T
        • Matsui H
        • Horiguchi H
        • Fushimi K
        • Yasunaga H
        Recombinant human soluble thrombomodulin and mortality in severe pneumonia patients with sepsis-associated disseminated intravascular coagulation: an observational nationwide study.
        J Thromb Haemost. 2015; 13: 31-40
        • Takazono T
        • Nakamura S
        • Imamura Y
        • Yoshioka S
        • Miyazaki T
        • Izumikawa K
        • et al.
        A retrospective comparative study of recombinant human thrombomodulin and gabexate mesilate in sepsis-induced disseminated intravascular coagulation patients.
        J Infect Chemother. 2014; 20: 484-488
        • Ito T
        • Kawahara K
        • Okamoto K
        • Yamada S
        • Yasuda M
        • Imaizumi H
        • et al.
        Proteolytic cleavage of high mobility group box 1 protein by thrombin-thrombomodulin complexes.
        Arterioscler Thromb Vasc Biol. 2008; 28: 1825-1830
        • Shi CS
        • Shi GY
        • Hsiao SM
        • Kao YC
        • Kuo KL
        • Ma CY
        • et al.
        Recombinant soluble thrombomodulin for postoperative disseminated intravascular coagulation.
        Blood. 2008; 112: 3661-3670
        • Van de Wouwer M
        • Plaisance S
        • De Vriese A
        • Waelkens E
        • Collen D
        • Persson J
        • et al.
        The lectin-like domain of thrombomodulin interferes with complement activation and protects against arthritis.
        J Thromb Haemost. 2006; 4: 1813-1824
        • Yamakawa K
        • Ogura H
        • Fujimi S
        • Morikawa M
        • Ogawa Y
        • Mohri T
        • et al.
        Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis.
        Intensive Care Med. 2013; 39: 644-652
        • Moll S
        • Lindley C
        • Pescatore S
        • Morrison D
        • Tsuruta K
        • Mohri M
        • et al.
        Phase I study of a novel recombinant human soluble thrombomodulin, ART-123.
        J Thromb Haemost. 2004; 2: 1745-1751
        • Yoshimura J
        • Yamakawa K
        • Ogura H
        • Umemura Y
        • Takahashi H
        • Morikawa M
        • et al.
        Benefit profile of recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis.
        Crit Care. 2015; 19: 78
        • Kato T
        • Sakai T
        • Kato M
        • Hagihara M
        • Hasegawa T
        • Matsuura K
        • et al.
        Recombinant human soluble thrombomodulin administration improves sepsis-induced disseminated intravascular coagulation and mortality: a retrospective cohort study.
        Thromb J. 2013; 11: 3
        • Ogawa Y
        • Yamakawa K
        • Ogura H
        • Kiguchi T
        • Mohri T
        • Nakamori Y
        • et al.
        Recombinant human soluble thrombomodulin improves mortality and respiratory dysfunction in patients with severe sepsis.
        J Trauma Acute Care Surg. 2012; 72: 1150-1157
        • Hashimoto D
        • Chikamoto A
        • Miyanari N
        • Ohara C
        • Kuramoto M
        • Horino K
        • et al.
        Recombinant soluble thrombomodulin for postoperative disseminated intravascular coagulation.
        J Surg Res. 2015; 197: 405-411